Mürdter TE - Search Results

1

Performance comparison of narrow-bore and capillary liquid-chromatography for non-targeted metabolomics profiling by HILIC-QTOF-MS.

Neef SK, Hofmann U, Mürdter TE, Schwab M, Haag M. Neef SK, et al. Among authors: murdter te. Talanta. 2023 Aug 1;260:124578. doi: 10.1016/j.talanta.2023.124578. Epub 2023 Apr 22. Talanta. 2023. PMID: 37119797

2

Treatment of lung cancer via telomerase inhibition: self-assembled nanoplexes versus polymeric nanoparticles as vectors for 2'-O-Methyl-RNA.

Nafee N, Schneider M, Friebel K, Dong M, Schaefer UF, Mürdter TE, Lehr CM. Nafee N, et al. Among authors: murdter te. Eur J Pharm Biopharm. 2012 Apr;80(3):478-89. doi: 10.1016/j.ejpb.2011.11.019. Epub 2011 Dec 17. Eur J Pharm Biopharm. 2012. PMID: 22198416

3

Impact of mistletoe lectin binding in breast cancer.

Fritz P, Dippon J, Kierschke T, Siegle I, Möhring A, Moisa A, Mürdter TE. Fritz P, et al. Among authors: murdter te. Anticancer Res. 2004 Mar-Apr;24(2C):1187-92. Anticancer Res. 2004. PMID: 15154645 Free article.

4

Growth/adhesion-regulatory tissue lectin galectin-3: stromal presence but not cytoplasmic/nuclear expression in tumor cells as a negative prognostic factor in breast cancer.

Moisa A, Fritz P, Eck A, Wehner HD, Mürdter T, Simon W, Gabius HJ. Moisa A, et al. Anticancer Res. 2007 Jul-Aug;27(4B):2131-9. Anticancer Res. 2007. PMID: 17695496 Free article.

5

Expression and function of beta-glucuronidase in pancreatic cancer: potential role in drug targeting.

Sperker B, Werner U, Mürdter TE, Tekkaya C, Fritz P, Wacke R, Adam U, Gerken M, Drewelow B, Kroemer HK. Sperker B, et al. Among authors: murdter te. Naunyn Schmiedebergs Arch Pharmacol. 2000 Aug;362(2):110-5. doi: 10.1007/s002100000260. Naunyn Schmiedebergs Arch Pharmacol. 2000. PMID: 10961372

6

[Treatment of cancer with cytostatics: results with high dose therapy with cyclophosphamide and drug targeting with doxorubicin].

Busse D, Kroemer HK, Sperker B, Mürdter TE. Busse D, et al. Among authors: murdter te. Pharm Unserer Zeit. 1998 Sep;27(5):216-22. doi: 10.1002/pauz.19980270507. Pharm Unserer Zeit. 1998. PMID: 9800467 Review. German. No abstract available.

7

V79 Chinese hamster cells genetically engineered for polymorphic cytochrome P450 2D6 and their predictive value for humans.

Krebsfaenger N, Mürdter TE, Zanger UM, Eichelbaum MF, Doehmer J. Krebsfaenger N, et al. Among authors: murdter te. ALTEX. 2003;20(3):143-54. ALTEX. 2003. PMID: 12947487 Free article.

8

Telomeres and telomerase as novel drug targets: reflections on the 2009 Nobel Prize in Physiology or Medicine.

Dong M, Mürdter TE, Klotz U. Dong M, et al. Among authors: murdter te. Eur J Clin Pharmacol. 2010 Jan;66(1):1-3. doi: 10.1007/s00228-009-0758-9. Epub 2009 Nov 21. Eur J Clin Pharmacol. 2010. PMID: 19936723 No abstract available.

9

Biopharmaceutical characterization of the telomerase inhibitor BRACO19.

Taetz S, Baldes C, Mürdter TE, Kleideiter E, Piotrowska K, Bock U, Haltner-Ukomadu E, Mueller J, Huwer H, Schaefer UF, Klotz U, Lehr CM. Taetz S, et al. Among authors: murdter te. Pharm Res. 2006 May;23(5):1031-7. doi: 10.1007/s11095-006-0026-y. Epub 2006 May 4. Pharm Res. 2006. PMID: 16715394

10

Decomposition of the telomere-targeting agent BRACO19 in physiological media results in products with decreased inhibitory potential.

Taetz S, Mürdter TE, Zapp J, Boettcher S, Baldes C, Kleideiter E, Piotrowska K, Schaefer UF, Klotz U, Lehr CM. Taetz S, et al. Among authors: murdter te. Int J Pharm. 2008 Jun 5;357(1-2):6-14. doi: 10.1016/j.ijpharm.2008.01.026. Epub 2008 Jan 20. Int J Pharm. 2008. PMID: 18313869

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

107 results

Search Page

Filters